In 1959 it was decided to treat selected cases by infusion of methotrexate continuously into the internal iliac artery in large doses, with the administration intermittently of Leucovorin (citrovorum factor) to combat general toxicity. This technique has been previously applied to cases of head and neck cancer by Sullivan with encouraging results (Sullivan et al. 959) .
A technique has been evolved which allows treatment to be given continuously for ten to twelve days, a course which may be repeated two or three times. A muscle-splitting abdominal incision is made on each side to expose the internal iliac artery extraperitoneally, and a length of polythene tubing is introduced into the artery just below the bifurcation by a method akin to Seldinger arteriography. It is secured to the arterial wall by interrupted sutures. A pursestring suture at the point of entry is not necessary. About 1 cm of tubing remains in the artery and is arranged to terminate above the first (posterior) branch. The polythene tubing is brought out of the abdomen by a stab incision near the anterior superior iliac spine. The position may be checked by injecting fluorescein down the tubes, and observing the distribution of the dye by a Wood's lamp.
A continuous infusion of methotrexate amounting to 25-30 mg/l. of normal dextrose saline every twenty-four hours, is infused on each side, a Bowman pump having been modified to take the twin supplies necessary to administer 50-60 mg of methotrexate each day, delivered directly to the tumour bed. To counteract toxicity to the bone marrow and elsewhere, 24 mg of citrovorum factor is given by divided intramuscular doses each day. Collapsible plastic bottles of infusion fluid are preferred, to lower the riskofairembolus.
Toxicity was demonstrated pictorially to be centred on bone marrow and gut. To guard against overdosage, a daily white blood count must be taken (Fig 1) and a watch kept for stomatitis and diarrhoea. Using the dosage Fig 1 Graph showing details of white blood count through two courses of treatment with intra-arterial methotrexate and intramuscular citrovorum factor schedule described, treatment is maintained for ten to fourteen days, by which time the total W.B.C. has fallen to limits of safety, usually just below 2,000. The tubing is then temporarily sealed and the patient allowed to recover from the toxicity. A further one or two courses may be given. At the end of a third course, further improvement is not usually observed. The lack of general malaise felt by the patient is noteworthy.
At the end of treatment the sealed end of the tubing is buried under the skin, whence it could be retrieved if further treatment were necessary. Biopsies and photographs are taken at regular intervals, and a study made of effects on iliac and sternal bone marrow.
Of 23 cases treated, 20 were treated to 'optimal' toxicity. Treatment was incomplete in 3 for technical reasons. In 5 cases treatment was followed by Wertheim's hysterectomy, where there had been doubt as to the operability before infusion. All the remaining lesions showed some regression, but this stopped short of disappearance with the exception of 2 cases. There were 3 deaths early in the series, all in patients with advanced cancer.
One patient with Stage II carcinoma of cervix had refused Wertheim's hysterectomy; she had complete clinical regression of her tumour (Trussell & Mitford-Barberton 1961) , and when last seen nine months after treatment showed no evidence of recurrence.
A second case, thought at first to be carcinoma of endocervix, proved to be an adeno-acanthoma of the lower part of the uterine body and was treated with methotrexate followed by Wertheim's hysterectomy. At operation, the site of the primary lesion in the body could be easily identified (Fig 2) but repeated histological section showed no trace of carcinoma. There were, however, adeno-acanthomatous deposits in glands on the pelvic wall.
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The Management of Leukemia in Pregnancy The coincidence of pregnancy and leukemia is fortunately extremely rare. Forkner (1938) found only 36 acceptable reports, and by 1960 there were still only about 150 (Hayhoe 1960) . Leukimia is a rare disease, and its age distribution and short fatal course account for the rarity with which it is found in association with pregnancy. Chronic lymphocytic leukemia is a disease of later life; it hardly ever occurs during the childbearing years, and is in any case less common in women. The mean survival of chronic granulo-cytic leukaemia is less than three years, and that of acute leukxemia about three months. The incidence of chronic granulocytic leukaemia rises with increasing age during the child-bearing years, but that of acute leukemia is evenly distributed. Of the 150 cases of coincident leukemia and pregnancy referred to by Hayhoe, 56 % were of chronic granulocytic, 41 % of acute, and only 3% of chronic lymphocytic leukemia.
In. chronic granulocytic leukwemia there is no evidence of impaired fertility, and in most reported cases of coexistent pregnancy conception occurred when the disease was already established although the -diagnosis was sometimes made during or after pregnancy in symptomless cases. Acute leukxemia may lead to impaired fertility
